Matias Kalevi Kinnunen

Mr. Matias Kalevi Kinnunen


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MKMatias Kalevi Kinnunen
Matias Kalevi Kinnunen
XLXiaonan Liu
Xiaonan Liu
ENElina H Niemelä
Elina H Niemelä
TÖTiina Öhman
Tiina Öhman
LGLisa Gawriyski
Lisa Gawriyski
MVMarkku Varjosalo
Markku Varjosalo
Chromosomal translocations creating fusion genes are common cancer drivers. The oncogenic ETV6-NTRK3 (EN) gene fusion joins the sterile alpha domain of the ETV6 transcription factor with the tyrosine kinase domain of the neurotrophin-3 receptor NTRK3. Four EN variants with alternating break points have since been detected in a wide range of human cancers. To provide molecular level insight into EN oncogenesis, we employed a proximity labeling mass spectrometry approach to define the molecular context of the fusions. We identify in total 237 high-confidence interactors, which link EN fusions to several key signaling pathways, including ERBB, insulin and JAK/STAT. We then assessed the effects of EN variants on these pathways, and showed that the pan NTRK inhibitor Selitrectinib (LOXO-195) inhibits the oncogenic activity of EN2, the most common variant. This systems-level analysis defines the molecular framework in which EN oncofusions operate to promote cancer and provides some mechanisms for therapeutics.